Title : Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53 - Chiorean_2012_Cancer.Chemother.Pharmacol_70_25 |
Author(s) : Chiorean EG , Sanghani S , Schiel MA , Yu M , Burns M , Tong Y , Hinkle DT , Coleman N , Robb B , LeBlanc J , Clark R , Bufill J , Curie C , Loehrer PJ , Cardenes H |
Ref : Cancer Chemother Pharmacol , 70 :25 , 2012 |
Abstract : Chiorean_2012_Cancer.Chemother.Pharmacol_70_25 |
ESTHER : Chiorean_2012_Cancer.Chemother.Pharmacol_70_25 |
PubMedSearch : Chiorean_2012_Cancer.Chemother.Pharmacol_70_25 |
PubMedID: 22610353 |
Chiorean EG, Sanghani S, Schiel MA, Yu M, Burns M, Tong Y, Hinkle DT, Coleman N, Robb B, LeBlanc J, Clark R, Bufill J, Curie C, Loehrer PJ, Cardenes H (2012)
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53
Cancer Chemother Pharmacol
70 :25
Chiorean EG, Sanghani S, Schiel MA, Yu M, Burns M, Tong Y, Hinkle DT, Coleman N, Robb B, LeBlanc J, Clark R, Bufill J, Curie C, Loehrer PJ, Cardenes H (2012)
Cancer Chemother Pharmacol
70 :25